BeiGene has announced that its Tevimbra (tislelizumab) has been approved by the European Commission (EC) as part of a ...

Sino-American biotech BeiGene (Nasdaq: ONC; HKEX 06160) today announced that the European Commission has approved Tevimbra ...

BeiGene's innovative cancer treatments, Brukinsa and Tevimbra, are driving growth. Click for a look at ONC and its latest ...

BeiGene has decided to stop the development ... advanced PD-L1-positive non-small cell lung cancer (NSCLC). "We evaluate our clinical programmes to focus our resources on the most promising ...

Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET. Summit disclosed some preliminary results of its HARMONi-6 trial, conducted in ...

The intriguing VEGFxPD-1 bispecific antibody space gained oomph with phase III results disclosed April 23 by Akeso ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

At the first pre-specified interim analysis of the 532-patient Chinese study, ivonescimab plus chemotherapy “decisively beat” BeiGene ... of non-small cell lung cancer but also marks a ...

People with lung cancer have no shortage of instructions ... ThymeCarel Medscape Live, BeiGene, Blue Note Therapeutics, and Oxford University Press. Source Reference: Lai-Kwon J, et al ...

The patent in question was related to Pharmacyclics’ allegations of infringement by BeiGene’s cancer drug BRUKINSA® (zanubrutinib). The USPTO’s Final Written Decision came as a result of a post-grant ...